Novel Methods for Arrhythmia Detection: Preliminary Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

220 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-05-01

Study Completion Date

2017-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Approximately 20-25% of strokes are of cardioembolic origin, atrial fibrillation (AF) being a significant cause of cardioembolic strokes. AF is often symptomless and intermittent, making its detection a clinical challenge. Currently the golden standard for diagnosis of AF is by 12-lead electrocardiogram (ECG) or any other ECG-strip.

The aim of the study is to assess the potential of chest strap as an ECG monitor, especially in arrhythmia detection by cardiologist and algorithm.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Atrial Fibrillation Detection: 24 Hour Study

NCT03507335

Arrhythmia Atrial Stroke

COMPLETED

Portable Measurement Methods Combined With Artificial Intelligence in Detection of Atrial Fibrillation

NCT04917653

Atrial Fibrillation Heart Rate Fast Heart Rate Low +1 more

UNKNOWN

Know Your Pulse Post Stroke-Measurement of Peripheral Pulse for Detection of Atrial Fibrillation After Ischemic Stroke

NCT01858779

Stroke Atrial Fibrillation

COMPLETED

Improving DEtection of Atrial fibriLlation in Primary Care With the MyDiagnostick

NCT02270151

Atrial Fibrillation

COMPLETED PHASE3

Evaluation of 5 Days Holter and 30 Days Thumb-ECG for Detection of Atrial Fibrillation in Stroke Patients

NCT02261766

Atrial Fibrillation Stroke

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study design was a prospective case-control multicenter study at three sites in Finland. Study material was collected in internal medicine emergency departments, cardiology wards and cardiology examination units of participating hospitals, Kuopio University Hospital, Helsinki University Central Hospital, Meilahti and North Karelia Central Hospital, Joensuu. The study design was approved by University of Eastern Finland ethics committee (237/2017).

Study participants received a written information sheet about the study and were provided with an opportunity to ask questions concerning the study. A written informed consent was signed by the participants, including a permission to use patient's medical records.

Screening of study participants was made in participating hospitals from admitted patients in May - September 2017. The inclusion criteria for study group patients was atrial fibrillation confirmed by a doctor-interpreted 12-lead ECG, taken for medical reasons. Exclusion criteria were: body mass index (BMI) over 33; implanted pacemaker device; 12-lead ECG findings of left bundle branch block (LBBB) or right bundle branch block (RBBB); medical condition requiring immediate treatment that would be delayed by the study measurements; serious infectious disease. Control group consisted of patients with normal sinus rhythm in 12-lead ECG.

Demographics of study patients, including age, gender, previous medical history (as reported by patient or from patient medical records), length, weight and BMI, was recorded.

First, a 12-lead ECG was taken over a period of 10 seconds for rhythm confirmation, after which the ECG electrodes were removed. In the next step, altogether 5 wet electrodes were attached to patient to record ECG with Faros 360 Holter device (Mega Elektroniikka, Kuopio, Finland; device 1) to be used as golden standard for rhythm monitoring. Simultaneously a heart rate monitoring chest strap (Suunto Movesense, Suunto, Vantaa, Finland; device 2) and wrist band photoplethysmography (PPG) (Empatica E4, Empatica inc., Cambridge, United States) was applied. A total of 5 min recording was made.

The data from heart rate chest strap was sent via Bluetooth connection to a mobile phone, from which it was transferred via a cable to study computer; the data from Faros Holter device was recorded to device´s internal memory card and transferred to analyzing software. PPG data were transferred to MATLAB® software version R2017b for pre-processing and analysis. The data collected was anonymized and ECG data from chest strap and Holter device was analyzed using MATLAB software.

The quality of the ECG-strip was defined as good (no or only minor artefacts), average (artefacts but QRS and/or P-wave identifiable) or poor (major artefacts, no identifiable QRS and/or P-wave) by the cardiologist. The rhythm from the ECG-strips was divided to three categories: sinus rhythm (SR), atrial fibrillation (AF) or other/inconclusive. The cardiologists also assessed the possibility to detect P-waves from the ECG-strips with sinus rhythm (yes/no).

The study population consisted of total 220 patients. According to the initial 12-lead ECG, total 110 patients with atrial fibrillation were collected, and control group consisted of 110 patients with normal sinus rhythm. The initial 12-lead ECG was only used to recruitment process of patients; later the division to sinus rhythm, atrial fibrillation or other rhythm used in the final analysis was made according to the cardiologist-interpreted Holter ECG.

Two commonly used AF detection algorithms were used in this work. Algorithms were used to demonstrate possibilities of automatic screening of AF using chest strap ECG devices with automated analysis.

Holter ECG serving as golden standard a total of 218 patients were included and 2 were excluded in the analysis. 2 of 220 3-lead Holter ECGs could be classified neither as sinus rhythm nor atrial fibrillation. One of them converted from atrial flutter to sinus rhythm during analysis and the quality of other ECG was insufficient for rhythm analysis. These two Holter ECGs and the corresponding chest strap ECGs were excluded from final analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Atrial fibrillation

Patients in atrial fibrillation as recorded by 3-lead Holter.

Heart rate monitor chest strap

Intervention Type DEVICE

Simultaneously with 5min Holter recording, 5min recording of chest strap ECG.

Wrist band photoplethysmography

Intervention Type DEVICE

Simultaneously with 5min Holter recording, 5min recording wrist band photoplethysmography.

Sinus rhythm

Patients in sinus rhythm as recorded by 3-lead Holter.

Heart rate monitor chest strap

Intervention Type DEVICE

Simultaneously with 5min Holter recording, 5min recording of chest strap ECG.

Wrist band photoplethysmography

Intervention Type DEVICE

Simultaneously with 5min Holter recording, 5min recording wrist band photoplethysmography.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Heart rate monitor chest strap

Simultaneously with 5min Holter recording, 5min recording of chest strap ECG.

Intervention Type DEVICE

Wrist band photoplethysmography

Simultaneously with 5min Holter recording, 5min recording wrist band photoplethysmography.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Atrial fibrillation in 12-lead ECG

Exclusion Criteria

* body mass index (BMI) over 33
* implanted pacemaker device
* 12-lead ECG findings of left bundle branch block (LBBB) or right bundle branch block (RBBB)
* medical condition requiring immediate treatment that would be delayed by the study measurements
* serious infectious disease

Eligible Sex

ALL

Accepts Healthy Volunteers

No